Abstract:Background: Following solid organ transplantation, tacrolimus (TAC) is an essential drug in the immunosuppressive strategy. Its use constitutes a challenge due to its narrow therapeutic index and its high inter- and intra-pharmacokinetic (PK) variability. As the contribution of the gut microbiota to drug metabolism is now emerging, it might be explored as one of the factors explaining TAC PK variability. Herein, we explored the consequences of TAC administration on the gut microbiota composition. Reciprocally, we studied the contribution of the gut microbiota to TAC PK, using a combination of in vivo and in vitro models. Results: TAC oral administration in mice resulted in compositional alterations of the gut microbiota, namely lower evenness and disturbance in the relative abundance of specific bacterial taxa. Compared to controls, mice with a lower intestinal microbial load due to antibiotics administration exhibit a 33% reduction in TAC whole blood exposure and a lower inter-individual variability. This reduction in TAC levels was strongly correlated with higher expression of the efflux transporter ABCB1 (also known as the p-glycoprotein (P-gp) or the multidrug resistance protein 1 (MDR1)) in the small intestine. Conventionalization of germ-free mice confirmed the ability of the gut microbiota to downregulate ABCB1 expression in a site-specific fashion. The functional inhibition of ABCB1 in vivo by zosuquidar formally established the implication of this efflux transporter in the modulation of TAC PK by the gut microbiota. Furthermore, we showed that polar bacterial metabolites could recapitulate the transcriptional regulation of ABCB1 by the gut microbiota, without affecting its functionality. Finally, whole transcriptome analyses pinpointed, among others, the Constitutive Androstane Receptor (CAR) as a transcription factor likely to mediate the impact of the gut microbiota on ABCB1 transcriptional regulation. Conclusions: We highlight for the first time how the modulation of ABCB1 expression by bacterial metabolites results in changes in TAC PK, affecting not only blood levels but also the inter-individual variability. More broadly, considering the high number of drugs with unexplained PK variability transported by ABCB1, our work is of clinical importance and paves the way for incorporating the gut microbiota in prediction algorithms for dosage of such drugs. Video Abstract.

Manipulating the Expression of SARP Family Regulator BulZ and Its Target Gene Product to Increase Tacrolimus Production

Enhancing the Production of Tacrolimus by Engineering Target Genes Identified in Important Primary and Secondary Metabolic Pathways and Feeding Exogenous Precursors

Combining Metabolomics and Network Analysis to Improve Tacrolimus Production in Streptomyces Tsukubaensis Using Different Exogenous Feedings

Generation of high rapamycin producing strain via rational metabolic pathway-based mutagenesis and further titer improvement with fed-batch bioprocess optimization.

FkbN and Tcs7 are pathway-specific regulators of the FK506 biosynthetic gene cluster in Streptomyces tsukubaensis L19

Enhanced Astaxanthin Production in S. Cerevisiae by Combinatorial Engineering of Gene Targets Outside the Synthetic Pathway

Elevation of FK506 Production by Regulatory Pathway Engineering and Medium Optimization in Streptomyces Tsukubaensis

Balancing carbon flux rebalancing around phosphoenolpyruvate node for enhancement of FK506 production in Streptomyces tsukubaensis

Overproduction of lactimidomycin by cross-overexpression of genes encoding Streptomyces antibiotic regulatory proteins

Improving the production of carbamoyltobramycin by an industrial Streptoalloteichus tenebrarius through metabolic engineering

Engineering of the LysR Family Transcriptional Regulator FkbR1 and Its Target Gene to Improve Ascomycin Production

Co-expression of a SARP Family Activator ChlF2 and a Type II Thioesterase ChlK Led to High Production of Chlorothricin in Streptomyces antibioticus DSM 40725

Effect of various antibiotics on the tacrolimus producing strain

Gut microbiome modulates tacrolimus pharmacokinetics through the transcriptional regulation of ABCB1

A Regulator Based “Semi-Targeted” Approach to Activate Silent Biosynthetic Gene Clusters

Enhancement of Rapamycin Production by Metabolic Engineering in Streptomyces Hygroscopicus Based on Genome-Scale Metabolic Model

Insights into the Metabolic Mechanism of Rapamycin Overproduction in the Shikimate-Resistant Streptomyces Hygroscopicus Strain Uv-Ii Using Comparative Metabolomics

Improvement of FK506 Production in Streptomyces Tsukubaensis by Genetic Enhancement of the Supply of Unusual Polyketide Extender Units Via Utilization of Two Distinct Site-Specific Recombination Systems

Rational screening for high production tacrolimus-producing strain

Negative regulation of bleomycins biosynthesis by ArsR/SmtB family repressor BlmR in Streptomyces verticillus

Genome-scale metabolic network guided engineering of Streptomyces tsukubaensis for FK506 production improvement